Brief: Cocrystal Pharma Reports Mostly Positive Results From A Phase 1 Study With Its Oral Antiviral Cc-42344 For The Treatment Of Pandemic And Seasonal Influenza A

Cocrystal Pharma

19/12/2022 13:08

Dec 19 (Reuters) - Cocrystal Pharma Inc  COCP.O :
    * COCRYSTAL PHARMA REPORTS HIGHLY FAVORABLE SAFETY AND
TOLERABILITY RESULTS FROM A PHASE 1 STUDY WITH ITS ORAL
ANTIVIRAL CC-42344 FOR THE TREATMENT OF PANDEMIC AND SEASONAL
INFLUENZA A
    * ABOUT 50% OF PARTICIPANTS WHO GOT SINGLE DOSE OF CC-42344
ACROSS
ALL DOSE LEVELS EXPERIENCED ADVERSE EVENTS
    * IN MULTIPLE-DOSE SECTION OF STUDY, INCIDENCE OF ADVERSE
EVENTS
WAS 67% FOR BOTH CC-42344 (50 TO 200 MG) AND PLACEBO
    * VAST MAJORITY OF ADVERSE EVENTS WERE MILD IN SEVERITY
    * THERE WERE NO SERIOUS ADVERSE EVENTS OR DRUG
DISCONTINUATION DUE
TO ADVERSE EVENTS
    * PLANS TO APPLY TO UK MEDICINES AND HEALTHCARE PRODUCTS
REGULATORY AGENCY TO CONDUCT A PHASE 2A HUMAN CHALLENGE STUDY IN
EARLY 2023

Source text for Eikon:  ID:nGNX481vzR 
Further company coverage:  COCP.O 
 ((Reuters.Briefs@thomsonreuters.com))